Australia secured more than 84 million doses of potential COVID-19 vaccines

Australia secured more than 84 million doses of potential COVID-19 vaccines

AstraZeneca scored another deal

As the pharmaceutical companies are getting close to releasing a viable #COVID-19 vaccine, countries worldwide are starting to secure millions of doses. The latest country to be part of this movement is Australia.

Australia announced that it would receive 3.8 million doses of the vaccine developed by AstraZeneca during the first two months of 2021. Currently, the vaccine is in Phase III of clinical trials in the US, Brazil, South Africa, and the UK. It hasn't revealed significant concerns, but it generated strong immune responses. Under the contract, the Australian government could purchase up to 30 million additional doses.

But the government’s mission doesn’t stop here. It will also purchase doses of the #vaccine developed by the University of Queensland (UQ). Unlike the ones from AstraZeneca, the UQ ones will be available mid-2021. The UQ is undergoing pre-clinical testing on 120 adults, following promising results on animal trials. From the University, the government will buy 51 million doses.

According to people familiar with the matter, vulnerable people and healthcare workers will be the first in line to receive the vaccine. However, things are still a topic of discussion among health officials.

Under the agreements, as mentioned before, the government has the possibility of purchasing additional doses. Also, it can donate or sell the remaining vaccines to other countries or international organizations. From nearly 85 million doses, if both vaccines are proven effective, Australia will have around 30 million doses to spare.

As far as both vaccines are concerned, they could require two doses per patient – an initial dose and a booster. The overall deal for both vaccines is of 1.24 billion.

Following today’s announcement, AstraZeneca stock price is trading 3.50% higher. Australia200 ended the session at +0.33%.

Read more about other pharma companies and their vaccines here!

Sources: investing.com, theguardian.com, yahoo.com


The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.